10-K Filing

GUIDED THERAPEUTICS INC CIK: 924515 FY 2011

Filing Information

Form Type	10-K
Accession Number	`0001121781-12-000081`
Period End Date	20111231
Filing Date	20120328
Fiscal Year	2011
Fiscal Period	FY
XBRL Instance	gthp-20111231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 69 Income Statement 38 Cash Flow Statement 72 Stockholders Equity 21

Balance Sheet 69 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$85.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$117.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$520.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$230.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	-	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $20 and $38 at December 31, 2011 and 2010, respectively	`AccountsReceivableNet`	$85.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $20 and $38 at December 31, 2011 and 2010, respectively	`AccountsReceivableNet`	$117.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Inventory, net of reserves of $64 and $0 at December 31, 2011 and 2010, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	-	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Inventory, net of reserves of $64 and $0 at December 31, 2011 and 2010, respectively	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$520.00K	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	47,299.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$54.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$30.00K	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	52,211.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.89M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.38M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	52,211.00	shares	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	47,299.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$37.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.03M	USD	Point-in-time
Capitalized cost of internally developed software for internal use	`CapitalizedComputerSoftwareNet`	$299.00K	USD	Point-in-time
Capitalized cost of internally developed software for internal use	`CapitalizedComputerSoftwareNet`	-	USD	Point-in-time
Other Assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$200.00K	USD	Point-in-time
Other Assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$386.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$536.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.42M	USD	Point-in-time
Total assets	`Assets`	$3.92M	USD	Point-in-time
Total assets	`Assets`	$4.31M	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$25.00K	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$30.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$25.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	-	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$614.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$362.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.10M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$915.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$885.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$757.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$332.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$453.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.73M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.77M	USD	Point-in-time
Long-term debt payable, less current portion	`LongTermDebt`	$4.00K	USD	Point-in-time
Long-term debt payable, less current portion	`LongTermDebt`	$31.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.73M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.80M	USD	Point-in-time
COMMITMENTS & CONTINGENCIES (Note 5)	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS & CONTINGENCIES (Note 5)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 48,491 and 47,299 shares issued and outstanding as of September 30, 2011 and December 31, 2010, respectively	`CommonStockValue`	$47.00K	USD	Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 48,491 and 47,299 shares issued and outstanding as of September 30, 2011 and December 31, 2010, respectively	`CommonStockValue`	$52.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$86.61M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$79.52M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-78.44M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-85.09M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$1.47M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$1.01M	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.58M	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.12M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$4.31M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.92M	USD	Point-in-time

Income Statement 38 line items

Line Item	Tag	Value	Unit	Period
Contract and grant revenue	`Revenues`	$3.60M	USD	Annual
Contract and grant revenue	`Revenues`	$3.36M	USD	Annual
Sales - Devices and Disposables	`SalesDevicesAndDisposables`	$25.00K	USD	Annual
Sales - Devices and Disposables	`SalesDevicesAndDisposables`	-	USD	Annual
Cost of goods sold	`CostOfGoodsAndServicesSold`	-	USD	Annual
Cost of goods sold	`CostOfGoodsAndServicesSold`	$-106.00K	USD	Annual
Gross loss	`GrossLoss`	$-81.00K	USD	Annual
Gross loss	`GrossLoss`	-	USD	Annual
Claim settlement	`IncreaseDecreaseInInsuranceSettlementsReceivable`	$-3.62M	USD	Annual
Claim settlement	`IncreaseDecreaseInInsuranceSettlementsReceivable`	-	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$2.78M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$1.80M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$131.00K	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$287.00K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.58M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$3.05M	USD	Annual
Total costs and expenses	`CostsAndExpenses`	$10.27M	USD	Annual
Total costs and expenses	`CostsAndExpenses`	$4.99M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-6.76M	USD	Annual
Operating loss	`OperatingIncomeLoss`	$-1.62M	USD	Annual
Other income	`OtherIncome`	$2.00K	USD	Annual
Other income	`OtherIncome`	$192.00K	USD	Annual
Interest expense	`InterestExpense`	$1.23M	USD	Annual
Interest expense	`InterestExpense`	$80.00K	USD	Annual
Loss from operations	`IncomeLossFromContinuingOperations`	$-2.85M	USD	Annual
Loss from operations	`IncomeLossFromContinuingOperations`	$-6.64M	USD	Annual
Provision for income taxes	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
Provision for income taxes	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	Annual
Net loss	`NetIncomeLoss`	$-6.64M	USD	Annual
Net loss	`NetIncomeLoss`	$-2.85M	USD	Annual
Preferred stock dividends	`DividendsPreferredStock`	-	USD	Annual
Preferred stock dividends	`DividendsPreferredStock`	$1.70M	USD	Annual
Net loss attributable to common stockholders	`NetIncomeLossAttributableToCommonStockholders`	$-6.64M	USD	Annual
Net loss attributable to common stockholders	`NetIncomeLossAttributableToCommonStockholders`	$-4.55M	USD	Annual
Basic and diluted net loss per share attributable to common stockholders	`EarningsPerShareBasicAndDiluted`	$-0.14	USD	Annual
Basic and diluted net loss per share attributable to common stockholders	`EarningsPerShareBasicAndDiluted`	$-0.12	USD	Annual
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	48,868.00	shares	Annual
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	38,596.00	shares	Annual

Cash Flow Statement 72 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-6.64M	USD	Annual
Net loss	`NetIncomeLoss`	$-2.85M	USD	Annual
Bad debt expense	`GainOnDebtRenigotiated`	$18.00K	USD	Annual
Bad debt expense	`GainOnDebtRenigotiated`	$3.00K	USD	Annual
Depreciation	`Depreciation`	$34.00K	USD	Annual
Depreciation	`Depreciation`	$7.00K	USD	Annual
Amortization and accretion of deferred financing costs, notes and warrants	`AmortizationOfFinancingCosts`	-	USD	Annual
Amortization and accretion of deferred financing costs, notes and warrants	`AmortizationOfFinancingCosts`	$1.09M	USD	Annual
Issuance of warrants in connection with settlement of claim	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	Annual
Issuance of warrants in connection with settlement of claim	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$3.62M	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$870.00K	USD	Annual
Stock based compensation	`ShareBasedCompensation`	$1.16M	USD	Annual
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	$230.00K	USD	Annual
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	-	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	$-520.00K	USD	Annual
Inventory	`IncreaseDecreaseInInventories`	-	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$47.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-50.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$18.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-24.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-243.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$187.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$121.00K	USD	Annual
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$82.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$141.00K	USD	Annual
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-168.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$39.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-180.00K	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$2.50M	USD	Annual
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$3.91M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-2.73M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-347.00K	USD	Annual
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	$-260.00K	USD	Annual
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	$-186.00K	USD	Annual
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-40.00K	USD	Annual
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-444.00K	USD	Annual
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-226.00K	USD	Annual
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-704.00K	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$3.06M	USD	Annual
Proceeds from issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$1.77M	USD	Annual
Proceeds from issuance of convertible notes payable to former debt holders - related parties	`ProceedsFromIssuanceOfConvertibleNotesRelatedParty`	-	USD	Annual
Proceeds from issuance of convertible notes payable to former debt holders - related parties	`ProceedsFromIssuanceOfConvertibleNotesRelatedParty`	$101.00K	USD	Annual
Payments made on notes payable	`PaymentsOfLoanCosts`	$23.00K	USD	Annual
Payments made on notes payable	`PaymentsOfLoanCosts`	$215.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$818.00K	USD	Annual
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$478.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.37M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.57M	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.07M	USD	Annual
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$3.61M	USD	Annual
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$230.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$230.00K	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$253.00K	USD	Annual
Cash paid for Interest	`InterestPaid`	$183.00K	USD	Annual
Conversion of preferred stock into common stock	`ConversionOfPreferredStockIntoCommonStock`	$1.96M	USD	Annual
Conversion of preferred stock into common stock	`ConversionOfPreferredStockIntoCommonStock`	-	USD	Annual
Dividends payable in the form of preferred stock converted into common stock	`DividendsPayablePreferredStockConvertedToCommonStock`	-	USD	Annual
Dividends payable in the form of preferred stock converted into common stock	`DividendsPayablePreferredStockConvertedToCommonStock`	$1.82M	USD	Annual
Conversion of bridge notes payable into common stock	`ConversionOfBridgeNotesPayableIntoCommonStock`	-	USD	Annual
Conversion of bridge notes payable into common stock	`ConversionOfBridgeNotesPayableIntoCommonStock`	$9.33M	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	-	USD	Annual
Conversion of accrued expenses into common stock	`ConversionOfAccruedExpensesIntoCommonStock`	$27.00K	USD	Annual
Conversion of interest to principal	`ConversionOfInterestOnlyToPrincipal`	-	USD	Annual
Conversion of interest to principal	`ConversionOfInterestOnlyToPrincipal`	$63.00K	USD	Annual
Conversion of accrued compensation to debt	`ConversionOfAccruedCompensationToDebt`	-	USD	Annual
Conversion of accrued compensation to debt	`ConversionOfAccruedCompensationToDebt`	$90.00K	USD	Annual
Deemed dividends in the form of warrants.	`DeemedDividendsInFormOfWarrants.`	-	USD	Annual
Deemed dividends in the form of warrants.	`DeemedDividendsInFormOfWarrants.`	$1.70M	USD	Annual

Stockholders Equity 21 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance, Amount	`StockholdersEquity`	$1.01M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$1.58M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquity`	$-11.97M	USD	Point-in-time
Conversion of convertible notes into common stock, Amount	`ConversionOfConvertibleNotesIntoCommonStockAmount`	$9.32M	USD	Annual
Conversion of preferred stock and accrued dividends into common stock, Amount	`ConversionOfPreferredStockAndAccruedDividendsIntoCommonStockAmount`	$1.82M	USD	Annual
Issuance of common stock, Amount	`IssuanceOfCommonStockAmount`	$1.77M	USD	Annual
Issuance of common stock, Amount	`IssuanceOfCommonStockAmount`	$3.06M	USD	Annual
Exercise of warrants/options, Amount	`ExerciseOfWarrantsoptionsAmount`	$818.00K	USD	Annual
Exercise of warrants/options, Amount	`ExerciseOfWarrantsoptionsAmount`	$478.00K	USD	Annual
Conversion of accrued compensation into common stock, Amount	`ConversionOfAccruedCompensationIntoCommonStockAmount`	$90.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$870.00K	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$1.16M	USD	Annual
Stock-based compensation expense, Amount	`StockbasedCompensationExpenseAmount`	$870.00K	USD	Annual
Issuance of warrants for claim settlement	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	Annual
Issuance of warrants for claim settlement	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$3.62M	USD	Annual
Conversion of debts into common stock, Amount	`ConversionOfDebtsIntoCommonStockAmount`	$27.00K	USD	Annual
Net Loss	`NetIncomeLoss`	$-6.64M	USD	Annual
Net Loss	`NetIncomeLoss`	$-2.85M	USD	Annual
Ending Balance, Amount	`StockholdersEquity`	$1.01M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$1.58M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquity`	$-11.97M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.